A5024922473- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Eicosanoids and Hypertension Pharmacology
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Melanoma and MAPK Pathways
- Genomics and Chromatin Dynamics
- Advanced Breast Cancer Therapies
- Endoplasmic Reticulum Stress and Disease
- Epigenetics and DNA Methylation
- Autophagy in Disease and Therapy
- Protein Tyrosine Phosphatases
- Advanced biosensing and bioanalysis techniques
- Ubiquitin and proteasome pathways
- Cancer Cells and Metastasis
- Glutathione Transferases and Polymorphisms
- RNA Research and Splicing
- Histone Deacetylase Inhibitors Research
- Calcium signaling and nucleotide metabolism
Institute for Research in Biomedicine
2018-2023
Biotechnology Institute Thurgau
2016
Carcinoma development in colorectal cancer is driven by genetic alterations numerous signaling pathways. Alterations the RAS-ERK1/2 pathway are associated with shortest overall survival for patients after diagnosis of metastatic disease, yet how RAS-ERK regulates metastasis remains unknown. In this study, we used an unbiased screening approach based on selection highly liver cells vivo to determine genes metastasis. From this, ERK1/2-controlled gene set (EMGS) was defined. EMGS increased...
Abstract MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms that are still poorly understood yet have important clinical implications. Oestrogen-receptor-positive (ER + ) BCa requires oestrogen for both growth and metastasis, albeit by ill-known mechanisms. Here we integrate proteomics, transcriptomics, epigenomics, chromatin accessibility functional assays from human syngeneic mouse models to show directly interacts with receptor alpha (ERα), thereby...
<div>Abstract<p>Carcinoma development in colorectal cancer is driven by genetic alterations numerous signaling pathways. Alterations the RAS-ERK1/2 pathway are associated with shortest overall survival for patients after diagnosis of metastatic disease, yet how RAS–ERK regulates metastasis remains unknown. In this study, we used an unbiased screening approach based on selection highly liver cells <i>in vivo</i> to determine genes metastasis. From this,...
<p>Supplementary Materials and Methods</p>
<p>SF1: The expression of ANGPT2 and CXCR4 in CRC; SF2: Expression levels ANGPT2, CXCR4, CXCL12, TEK VEGFA SW620_P SW620_LiM2 cells; SF3: upon downregulation upregulation.; SF4: CXCL1 IL10 is controlled by RAS-ERK signaling pathway; SF5: Correlation various genes BRAF-signature or CRIS subtypes across CRC tumors; ST1: mRNA comparisons; ST2: Hypergeometric test for Signature FC-1.75.up ( 15 genes) - KEGG.</p>
<p>Supplementary Materials and Methods</p>
<p>SF1: The expression of ANGPT2 and CXCR4 in CRC; SF2: Expression levels ANGPT2, CXCR4, CXCL12, TEK VEGFA SW620_P SW620_LiM2 cells; SF3: upon downregulation upregulation.; SF4: CXCL1 IL10 is controlled by RAS-ERK signaling pathway; SF5: Correlation various genes BRAF-signature or CRIS subtypes across CRC tumors; ST1: mRNA comparisons; ST2: Hypergeometric test for Signature FC-1.75.up ( 15 genes) - KEGG.</p>
<div>Abstract<p>Carcinoma development in colorectal cancer is driven by genetic alterations numerous signaling pathways. Alterations the RAS-ERK1/2 pathway are associated with shortest overall survival for patients after diagnosis of metastatic disease, yet how RAS–ERK regulates metastasis remains unknown. In this study, we used an unbiased screening approach based on selection highly liver cells <i>in vivo</i> to determine genes metastasis. From this,...